Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. besg

BESG SIGNED

Bioengineered exosomes based approaches for the effective treatment of non-small cell lung cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BESG project word cloud

Explore the words cloud of the BESG project. It provides you a very rough idea of what is the project "BESG" about.

gefitinib    smokers    patient    cell    clinical    acid    therapeutics    expectancy    occupational    besg    bioengineered    spc24    composing    model    pharmacokinetics    acids    sites    imaging    alcoholism    anti    metastasis    former    causes    pollution    dosage    reticuloendothelial    acceptable    loading    gef    exogenous    drugs    composition    clearance    cellular    proteins    payload    career    cancer    exosomes    sirna    era    site    natural    medicine    nanovesicles    evade    peptide    mesenchymal    culture    area    nsclcs    simultaneously    hsp4    drug    biodistribution    membrane    technologies    bypass    exo    protein    abstract    mscs    exposure    release    death    air    compliance    engineered    endogenous    nanotechnology    difficult    payloads    mechanism    small    predominant    precision    origin    xenograft    underlying    lung    stromal    res    carriers    mechanisms    reduce    nucleic    action    conjugation    principal    models    recognition    life    smoking    patients    egfr    cells    world    clinically    immune    inhibitor    trainings   

Project "BESG" data sheet

The following table provides information about the project.

Coordinator		 PERCUROS BV 

Organization address
address: PLESMANLAAN 1
city: LEIDEN
postcode: 2333 BZ
website: www.percuros.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Total cost 175˙572 €
 EC max contribution 175˙572 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2020
 Duration (year-month-day) from 2020-10-01   to  2022-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PERCUROS BV NL (LEIDEN) coordinator 175˙572.00

Map

 Project objective

ABSTRACT: Lung cancer is the principal cause of cancer-related death around the world and has become more predominant among former than current smokers. Smoking, alcoholism, air pollution, occupational exposure are among the main causes of non-small cell lung cancer (NSCLCs). It is difficult to simultaneously deliver therapeutics and nucleic acid to the target site. With the advancement of nanotechnology, a delivery system composing of cellular proteins which can bypass the reticuloendothelial system (RES) and have the ability to release payload at the specific target site is the necessity of the current era. Exosomes (Exo) are clinically acceptable, having protein membrane composition and the ability to deliver payload at specific target sites. Having endogenous origin, Exo evade immune recognition and clearance compared to exogenous nanovesicles. Exo are natural carriers of nucleic acids and they can be engineered to deliver siRNA as well as anti-cancer drugs. In this we propose the conjugation or covering of mesenchymal stromal cells (MSCs) derived exosomes with HSP4 peptide (target specific to NSCLCs) and loading them with Gefitinib (GEF), an EGFR inhibitor and SPC24 siRNA (target for NSCLCs and metastasis). The delivery of GEF and SPC24 siRNA using bioengineered exosomes (BESG) will reduce their dosage; improve patient compliance and life expectancy of patients. BESG will be evaluated for their uptake mechanisms and their mechanism of action in cell culture models of NSCLCs. BESG will specifically target the NSCLCs and release its payloads at cancer site. The underlying mechanisms, pharmacokinetics, biodistribution and anti-cancer activity will be evaluated in xenograft model of NSCLCs using advance imaging technologies. The BESG developed during this program will have a clinical potential and the trainings obtained through this program will help in career advancement in the area of drug delivery and precision medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BESG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BESG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

CRAS (2019)

Climate change and Resilience of Agricultural System: an econometric and computational analysis

Read More  

LiverMacRegenCircuit (2020)

Elucidating the role of macrophages in liver regeneration and tissue unit formation

Read More  

SSHelectPhagy (2019)

Regulation of Selective autophagy by sulfide through persulfidation of protein targets.

Read More